|Articles|August 26, 2022
Minimize Risks and Enhance Speed and Flexibility with Sterile Fill/Finish Support
Author(s)Eurofins
Join Eurofins BioPharma Product Testing and Vanrx (now part of Cytiva), for an in-depth discussion covering ways to eliminate human error and other associated risks when producing small batches of sterile GMP product for Phase 1 and 2 clinical trials. Learn how we can help increase speed and flexibility to drive your drug product into the clinic, and ultimately to patients faster.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
2
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
3
Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays
4
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences
5